Evidence map›Paper›PMID 41298786›Full record

ArticleScientific reports2025

Novel anti-prion compounds screening in prion-infected cell culture model combined with surface plasmon resonance analysis.

Mai Hazekawa, Daisuke Ishibashi, Andrea Altieri, Evgeniy A Spiridonov, Nikolai A Dmitriev, Evgeny R Lukyanenko, Emiliano Biasini, Alexander V Kurkin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mai HazekawaDepartment of Drug Delivery, Faculty of Pharmaceutical Science, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. mhaze@fukuoka-u.ac.jp.
Daisuke IshibashiDepartment of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Andrea AltieriChemistry Department of Lomonosov, Moscow State University, GSP-2, Leninskie Gory, 1/3, Moscow, 119991, Russia.
Evgeniy A SpiridonovChemistry Department of Lomonosov, Moscow State University, GSP-2, Leninskie Gory, 1/3, Moscow, 119991, Russia.
Nikolai A DmitrievChemistry Department of Lomonosov, Moscow State University, GSP-2, Leninskie Gory, 1/3, Moscow, 119991, Russia.
Evgeny R LukyanenkoChemistry Department of Lomonosov, Moscow State University, GSP-2, Leninskie Gory, 1/3, Moscow, 119991, Russia.
Emiliano BiasiniDulbecco Telethon Laboratory of Prions & Amyloids, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, Trento, 38123, Italy.
Alexander V KurkinChemistry Department of Lomonosov, Moscow State University, GSP-2, Leninskie Gory, 1/3, Moscow, 119991, Russia.

Funding

Japan Society for the Promotion of Science 22H02989Japan Society for the Promotion of Science 22K19497
6 · The paper itself

Abstract

Prions are misfolded proteins (PrP

Indexed as

Prion DiseasesPrionsPrPSc ProteinsSurface Plasmon ResonanceAnimalsCell LineDrug Evaluation, PreclinicalHumansPrion ProteinsSmall Molecule LibrariesPrion ProteinsPrionsPrPSc ProteinsSmall Molecule LibrariesDrug discovery, surface plasmon resonanceHit generationMedicinal chemistryPrion

Identifiers

PMID41298786
PMCPMC12748794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.